{"protocolSection":{"identificationModule":{"nctId":"NCT05892510","orgStudyIdInfo":{"id":"CT26024"},"organization":{"fullName":"University of Melbourne","class":"OTHER"},"briefTitle":"Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke","officialTitle":"Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke (EXTEND-AGNES TNK)"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-09-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2027-08-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-11-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-05-26","studyFirstSubmitQcDate":"2023-05-26","studyFirstPostDateStruct":{"date":"2023-06-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-06-13","lastUpdatePostDateStruct":{"date":"2023-06-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"University of Melbourne","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"Multicentre, prospective, Multi-arm Multi-stage (MAMS) seamless phase 2b/3 interventional randomized placebo-controlled double-blinded parallel-assignment (2 arms with 1:1 randomization) efficacy and safety trial to test intra-arterial tenecteplase at the completion of thrombectomy versus best practice in participants with anterior circulation LVO receiving mechanical thrombectomy within 24 hours of symptoms onset."},"conditionsModule":{"conditions":["Ischemic Stroke, Acute","Cerebrovascular Disorders","Brain Disorder","Central Nervous System Diseases"],"keywords":["Tenecteplase","Fibrinolytic agents","Thrombectomy","No-reflow"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":462,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Intra-arterial bolus of placebo (0.9% Sodium Chloride solution) representing standard of care (no intra-arterial thrombolytic treatment).","interventionNames":["Drug: Placebo"]},{"label":"Intra-arterial tenecteplase injection at the completion of thrombectomy","type":"EXPERIMENTAL","description":"intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion or in direct contact with the residual thrombus","interventionNames":["Drug: Intra-arterial tenecteplase injection at the completion of thrombectomy"]}],"interventions":[{"type":"DRUG","name":"Intra-arterial tenecteplase injection at the completion of thrombectomy","description":"Intra-arterial tenecteplase (0.062mg/kg, maximum 6.25mg) administered as a bolus at the completion of thrombectomy through a microcatheter at the site of the initial-but-now-retrieved intracranial occlusion, or in direct contact with the residual thrombus","armGroupLabels":["Intra-arterial tenecteplase injection at the completion of thrombectomy"]},{"type":"DRUG","name":"Placebo","description":"intra-arterial bolus of 0.9% Sodium Chloride solution","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Early Neurological Improvement (Phase 2b)","description":"Proportion of participants with Early Neurological Improvement (ENI) defined as NIHSS reduction\\>4","timeFrame":"24-36 hours from time of randomisation"},{"measure":"Functional independence (Phase 3)","description":"Proportion of participants with Modified Rankin Scale (mRS) 0-2 (functional independence)","timeFrame":"3 months"}],"secondaryOutcomes":[{"measure":"Functional improvement","description":"Reduction of ≥ 1 mRS category (ordinal analysis merging mRS categories 5-6)","timeFrame":"3 months"},{"measure":"Infarct growth","description":"Infarct growth volume on follow-up MRI or CT","timeFrame":"24 hours"},{"measure":"No-reflow","description":"Proportion of participants with radiological no-reflow on MR perfusion or CTP","timeFrame":"24 hours"},{"measure":"Symptomatic Intracerebral Hemorrhage","description":"Proportion of participants with sICH defined as parenchymal haematoma type 2 (PH2) or SAH/IVH within 36 hours combined with neurological deterioration leading to an increase of NIHSS ≥4 from baseline or leading to death","timeFrame":"36 hours"},{"measure":"All cause mortality","description":"Proportion of participants with death due to any cause","timeFrame":"3 months"},{"measure":"Quality of life assessment on EQ-5D","description":"EQ-5D score","timeFrame":"3 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult participants (age≥18 years) presenting with ischemic stroke with arterial LVO on CT/MR Angiogram of the intracranial internal carotid or middle cerebral artery (MCA) first segment (M1) or proximal second segment (M2) committed to thrombectomy using standard criteria within 24 hours of onset:\n* For 0-6 hours of symptom onset: Presence of arterial occlusion as defined above and ASPECTS≥3 on NCCT\n* For 6-24 hours of symptom onset: Additional imaging criteria on CTP or MRI perfusion of core volume \\<100ml.\n* Qualifying CT/MR within 4hrs of randomisation (repeat CT for transferred participants required if \\>4hr)\n* Pre-stroke Modified Rankin Scale (mRS) score of ≤2 (mild pre-existing disability permitted)\n* Local legal requirements for consent have been satisfied.\n\nExclusion Criteria:\n\n* Intracranial hemorrhage identified by CT or MRI\n* ASPECTS 0-2 on NCCT\n* CTP or MRI perfusion ischemic core volume \\>100ml if presenting within 6-24 hours from symptoms onset\n* Anticipated endovascular stenting required for intracranial or extracranial atherosclerotic stenosis/occlusion.\n* More than six retrieval attempts in the same vessel\n* Alteplase being infused within 30 minutes (\\~5x half-life) of anticipated trial drug administration\n* Contraindication to imaging with contrast agents\n* Any condition (eg.mid-arterial phase early venous filling) that in the judgment of investigators could impose hazards if study therapy is initiated\n* Pregnant women.\n* Current participation in another intervention research study that includes experimental interventions beyond standard-of-care.\n* Anticoagulation. INR ≤1.7 if on warfarin, and dabigatran reversal by idarucizumab are permitted.\n* Other standard contraindications to thrombolysis apart from time window.\n* Known terminal illness such that the participants would not be expected to survive a year.\n* Planned withdrawal of care or comfort care measures.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Felix Ng","role":"CONTACT","phone":"+03 9342 7000","email":"ng.f@unimelb.edu.au"}],"locations":[{"facility":"Royal Adelaide Hospital","city":"Adelaide","country":"Australia","contacts":[{"name":"Roy Drew","role":"CONTACT"},{"name":"Timothy Kleinig","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Princess Alexandra Hospital","city":"Brisbane","country":"Australia","contacts":[{"name":"Michael Devlin","role":"CONTACT"},{"name":"Michael Devlin","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-27.46794,"lon":153.02809}},{"facility":"Royal Brisbane and Women's Hospital","city":"Brisbane","country":"Australia","contacts":[{"name":"Andrew Wong","role":"CONTACT"},{"name":"Andrew Wong","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-27.46794,"lon":153.02809}},{"facility":"Canberra Hospital","city":"Canberra","country":"Australia","contacts":[{"name":"Peter Mews","role":"CONTACT"},{"name":"Peter Mews","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-35.28346,"lon":149.12807}},{"facility":"Alfred Hospital","city":"Melbourne","country":"Australia","contacts":[{"name":"Pamela Galindo","role":"CONTACT"},{"name":"Geoff Cloud","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Austin Hospital","city":"Melbourne","country":"Australia","contacts":[{"name":"Vincent Thijs","role":"CONTACT"},{"name":"Vincent Thijs","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Monash Medical Centre","city":"Melbourne","country":"Australia","contacts":[{"name":"Henry Ma","role":"CONTACT"},{"name":"Henry Ma","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"Royal Melbourne Hospital","city":"Melbourne","country":"Australia","contacts":[{"name":"David Jackson","role":"CONTACT"},{"name":"Felix Ng","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"John Hunter Hospital","city":"Newcastle","country":"Australia","contacts":[{"name":"Linda Belevski","role":"CONTACT"},{"name":"Carlos Garcia-Esperon","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-32.92715,"lon":151.77647}},{"facility":"Fiona Stanley Hospital","city":"Perth","country":"Australia","contacts":[{"name":"Darshan Ghia","role":"CONTACT"},{"name":"Darshan Ghia","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-31.95224,"lon":115.8614}},{"facility":"Liverpool Hospital","city":"Sydney","country":"Australia","contacts":[{"name":"Dennis Cordato","role":"CONTACT"},{"name":"Dennis Cordato","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Mark Parsons","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"Royal North Shore Hospital","city":"Sydney","country":"Australia","contacts":[{"name":"Alice Ma","role":"CONTACT"},{"name":"Alice Ma","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-33.86785,"lon":151.20732}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"}],"ancestors":[{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M16376","name":"Thrombosis","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke, Acute","relevance":"HIGH"},{"id":"M4894","name":"Brain Diseases","asFound":"Brain Disorders","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","asFound":"Cerebrovascular Disorders","relevance":"HIGH"},{"id":"M5432","name":"Central Nervous System Diseases","asFound":"Central Nervous System Diseases","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077785","term":"Tenecteplase"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M1911","name":"Tenecteplase","asFound":"Early Intervention","relevance":"HIGH"},{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"PhSol","name":"Pharmaceutical Solutions"}]}},"hasResults":false}